Clinical Drug Investigation

, Volume 28, Issue 7, pp 409–420

Pharmacokinetics, Safety and Tolerance of Voriconazole in Renally Impaired Subjects

Two Prospective, Multicentre, Open- Label, Parallel-Group Volunteer Studies


  • Samantha Abel
    • Pfizer Global Research and Development
  • Richard Allan
    • Pfizer Inc.
  • Kuan Gandelman
    • Pfizer Inc.
  • Konrad Tomaszewski
    • Pfizer Global Research and Development
  • David J. Webb
    • Clinical Pharmacology Unit, Centre for Cardiovascular ScienceUniversity of Edinburgh, Queen’s Medical Research Institute
  • Nolan D. Wood
    • Pfizer Global Research and Development
Original Research Article

DOI: 10.2165/00044011-200828070-00002

Cite this article as:
Abel, S., Allan, R., Gandelman, K. et al. Clin. Drug Investig. (2008) 28: 409. doi:10.2165/00044011-200828070-00002


Background and objectives:

Since little is known regarding the pharmacokinetics of voriconazole in renally impaired patients, two prospective, open-label, parallel-group volunteer studies were conducted to estimate the effect of renal impairment on the pharmacokinetics of oral voriconazole and intravenous voriconazole solubilized with sulphobutylether-β-cyclodextrin (SBECD), respectively.


In study A, male subjects with no (n = 6), mild (n = 6), moderate (n = 6) or severe (n = 6) renal impairment received one 200 mg dose of oral voriconazole. Voriconazole plasma levels were periodically assessed until 48 hours post-dose. In study B, male subjects with no (n = 6) or moderate (n = 7) renal impairment received multiple doses of intravenous voriconazole solubilized with SBECD (6 mg/kg twice daily [day 1] then 3 mg/kg twice daily [days 2–6] followed by a final dose of 3 mg/kg on the morning of day 7) at an infusion rate of 3 mg/kg/h. Voriconazole plasma levels were periodically assessed until 36 hours following the final dose. Pharmacokinetics were determined by non-compartmental methods.


The pharmacokinetics of voriconazole were unaffected in subjects with any degree of renal impairment in both studies. In study B, clearance of SBECD was proportional to creatinine clearance (r2 = 0.857). Although two subjects had >30% increase in serum creatinine from baseline, these changes did not correlate with SBECD trough levels (r2 = 0.053). The majority of subjects with moderate renal insufficiency were able to tolerate 7 days of intravenous voriconazole solubilized with SBECD.


These data suggest that renal impairment does not affect the pharmacokinetics of voriconazole. Furthermore, in subjects with moderate renal impairment, there is a strong linear correlation between SBECD clearance and creatinine clearance, and elevated SBECD levels do not necessarily correlate with increased serum creatinine levels (an indicator of worsening renal function).

Copyright information

© Adis Data Information BV 2008